Lycia Therapeutics
Summary active Updated Jun 29, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Lycia Therapeutics is a South San Francisco-based clinical-stage biotechnology company developing novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on autoimmune, inflammatory, and allergic diseases 12. The company was scientifically co-founded by Nobel laureate Carolyn Bertozzi, Ph.D. of Stanford University, and is led by CEO Aetna Wun Trombley, Ph.D. 123. Its lead candidates are LCA-0061, a cataLYTAC degrader of IgE targeting food allergy and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete the autoantibodies that cause Graves’ disease 12. The Series D was raised to advance the LYTAC pipeline toward early clinical proof of concept 12.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-25 | Series D | $75M | Janus Henderson Investors, Balyasny Asset Management | Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, Venrock Healthcare Capital Partners 123 |
Alongside the financing, Lycia appointed Amy Bachrodt as Chief Financial Officer and promoted Karen Flick to General Counsel 1.
What Investors Say
“By driving selective depletion of disease-causing proteins, we believe Lycia’s degraders could represent a potentially best-in-class option.” — Vish Sridharan, M.D., Janus Henderson, quoted in the Lycia Series D announcement, June 25, 2026 1
What Founders Say
“With this financing and strengthened leadership team now in place, we believe we are well-positioned to execute on our clinical programs.” — Aetna Wun Trombley, Ph.D., CEO, Lycia Therapeutics, June 25, 2026 1
Sources
-
GlobeNewswire, “Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel,” June 25, 2026. Accessed June 2026. https://www.globenewswire.com/news-release/2026/06/25/3317430/0/en/lycia-therapeutics-raises-75-million-in-oversubscribed-financing-and-strengthens-leadership-team-with-appointment-of-chief-financial-officer-and-general-counsel.html↩↩↩↩↩↩↩↩
-
Fierce Biotech, “Fierce Biotech Fundraising Tracker ‘26: Lycia raises $75M; Oblenio reels in $62M,” June 2026. Accessed June 2026. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-2↩↩↩↩↩
-
BioSpace, “Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel,” June 25, 2026. Accessed June 2026. https://www.biospace.com/press-releases/lycia-therapeutics-raises-75-million-in-oversubscribed-financing-and-strengthens-leadership-team-with-appointment-of-chief-financial-officer-and-general-counsel↩↩